Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

Ricardo Ariel Zimerman, Daniel do Nascimento Fonseca, Michael do Nascimento Correia, Renan Nascimento Barros, Dirce Costa Onety, Karla Cristina Petruccelli Israel, Emilyn Oliveira Guerreiro, José Erique Miranda Medeiros, Raquel Neves Nicolau, Luiza Fernanda Mendonça Nicolau, Rafael Xavier Cunha, Maria Fernanda Rodrigues Barroco, Patrícia Souza da Silva, Raysa Wanzeller de Souza Paulain, Claudia Elizabeth Thompson, Andy Goren, View ORCID ProfileCarlos Gustavo Wambier, View ORCID ProfileFlávio Adsuara Cadegiani
doi: https://doi.org/10.1101/2021.06.28.21259661
Ricardo Ariel Zimerman
1Hospital da Brigada Militar, Porto Alegre, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel do Nascimento Fonseca
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael do Nascimento Correia
3Hospital Regional José Mendes, Itacoatiara, Amazonas, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renan Nascimento Barros
4Hospital Municipal Jofre Cohen, Parintins, Amazonas, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirce Costa Onety
5Centro de Doenças Renais do Amazonas, Manaus, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karla Cristina Petruccelli Israel
5Centro de Doenças Renais do Amazonas, Manaus, Brazil
6Programa de Pós-Graduação em Medicina Tropical – FMT/UEA, Manaus, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilyn Oliveira Guerreiro
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Erique Miranda Medeiros
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raquel Neves Nicolau
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luiza Fernanda Mendonça Nicolau
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Xavier Cunha
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Fernanda Rodrigues Barroco
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrícia Souza da Silva
2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raysa Wanzeller de Souza Paulain
4Hospital Municipal Jofre Cohen, Parintins, Amazonas, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Elizabeth Thompson
7Department of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto Alegre
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andy Goren
8Applied Biology, Inc. Irvine, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Gustavo Wambier
9Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos Gustavo Wambier
Flávio Adsuara Cadegiani
8Applied Biology, Inc. Irvine, CA, USA
10Corpometria Institute, Brasilia, Brazil
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Flávio Adsuara Cadegiani
  • For correspondence: f.cadegiani@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Proxalutamide, a second-generation non-steroidal antiandrogen (NSAA), primarily developed for castration-resistant prostate cancer, demonstrated reduction in 28-day mortality rate of 77.7% in hospitalized COVID-19 patients in a double-blind, placebo-controlled, two-arm randomized clinical trial (RCT), through intention-to-treat (ITT) analysis. We observed a high 28-day mortality rate of patients that did not complete the 14-day treatment with proxalutamide, compared to the placebo arm. These differences may raise hypotheses to explain the wide differences between ITT and on-treatment (OT) analysis in terms of efficacy. Despite the inherent limitations of OT analysis, we aimed to respond to unanswered questions regarding the drug efficacy when the 14-day treatment with proxalutamide was complete, and secondarily understand the causality relationship between treatment interruption and mortality rate.

Methods This is a post-hoc exploratory analysis of a double-blinded, randomized, placebo-controlled, prospective, multicentric, two-arm RCT of 300mg-daily 14-day proxalutamide therapy for hospitalized COVID-19 patients not requiring mechanical ventilation. OT population excluded patients that did not complete the full 14-day course of therapy or died from COVID-19 complications within 24 hours of randomization. The primary outcome was the 28-day COVID-19 mortality rate. Secondary outcomes included median hospital length, 14-day and 28-day alive hospital discharge rate and 28-day all-cause mortality rate of those who discontinued intervention.

Results In total, 580 patients completed the 14-day treatment or died during treatment, including 288 patients in the proxalutamide arm and 292 patients in the placebo arm, with similar baseline characteristics between groups. The 28-day COVID-19 mortality rate was 4.2% in the proxalutamide group and 49.0% in the placebo group. The mortality risk ratio (RR) was 0.08 (95% CI, 0.05-0.15), with a number needed to treat (NNT) of 2.2 to prevent death. The median hospital length stay after randomization was 5 days (interquartile range [IQR] = 3 to 7.2 days) in the proxalutamide group and 9 days (IQR = 6 to 15 days) in the placebo group (p <0.001). The 28-day all-cause mortality rate of patients that received proxalutamide but interrupted treatment before 14 days was 79.3%, while those that received placebo and interrupted before 14 days was 52.8% (p = 0.054 between groups).

Conclusion The reduction in 28-day all-cause mortality rate with 14-day proxalutamide treatment for hospitalized COVID-19 patients was more significant while on treatment adhesion (92%), compared to the reduction when all patients enrolled in the proxalutamide arm were considered (77.7%). However, the magnitude of statistical significance of the reduction in all-cause mortality and the NNT were similar between the OT and ITT analysis. The apparent high mortality risk rate with early interruption of proxalutamide treatments suggests that strategies for treatment compliance should be reinforced for future RCTs with proxalutamide. (NCT04728802)

Competing Interest Statement

Kintor Pharmaceuticals, Ltd. manufactures and plans to market proxalutamide, and has an investigational new drug (IND) application under United States Food and Drugs Administration to conduct a Phase 3 study for proxalutamide for COVID-19. Applied Biology, Inc. has patents pending regarding antiandrogen therapy for COVID-19. Dr. Goren, Dr. McCoy, and Dr. Li are employees of Applied Biology, Inc. Dr. Cadegiani has served as a clinical director for Applied Biology, Inc. Dr. Wambier has served as an advisor to Applied Biology, Inc. The other authors have no conflict of interest to declare.

Clinical Trial

NCT04728802

Funding Statement

Kintor Pharmaceuticals, Ltd. manufactures and plans to market proxalutamide, and has an investigational new drug (IND) application under United States Food and Drugs Administration to conduct a Phase 3 study for proxalutamide for COVID-19. Applied Biology, Inc. has patents pending regarding antiandrogen therapy for COVID-19. Dr. Goren, Dr. McCoy, and Dr. Li are employees of Applied Biology, Inc. Dr. Cadegiani has served as a clinical director for Applied Biology, Inc. Dr. Wambier has served as an advisor to Applied Biology, Inc. The other authors have no conflict of interest to declare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by an ethics committee and registered in clinicaltrials.gov (NCT04728802), and also approved by Brazilian National Ethics Committee, approval number 4.513.425; CAAE 41909121.0.0000.5553; Comite de Etica em Pesquisa (CEP) of the Comite Nacional de Etica em Pesquisa (CONEP) of the Ministry of Health (MS). (CEP/CONEP/MS).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The mortality rates were not all-cause mortality rates, but COVID-19 related mortality rates. However, this change did not lead to changes in rates.

Data Availability

Data is available in case request is approved by the research team.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 13, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
Ricardo Ariel Zimerman, Daniel do Nascimento Fonseca, Michael do Nascimento Correia, Renan Nascimento Barros, Dirce Costa Onety, Karla Cristina Petruccelli Israel, Emilyn Oliveira Guerreiro, José Erique Miranda Medeiros, Raquel Neves Nicolau, Luiza Fernanda Mendonça Nicolau, Rafael Xavier Cunha, Maria Fernanda Rodrigues Barroco, Patrícia Souza da Silva, Raysa Wanzeller de Souza Paulain, Claudia Elizabeth Thompson, Andy Goren, Carlos Gustavo Wambier, Flávio Adsuara Cadegiani
medRxiv 2021.06.28.21259661; doi: https://doi.org/10.1101/2021.06.28.21259661
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
Ricardo Ariel Zimerman, Daniel do Nascimento Fonseca, Michael do Nascimento Correia, Renan Nascimento Barros, Dirce Costa Onety, Karla Cristina Petruccelli Israel, Emilyn Oliveira Guerreiro, José Erique Miranda Medeiros, Raquel Neves Nicolau, Luiza Fernanda Mendonça Nicolau, Rafael Xavier Cunha, Maria Fernanda Rodrigues Barroco, Patrícia Souza da Silva, Raysa Wanzeller de Souza Paulain, Claudia Elizabeth Thompson, Andy Goren, Carlos Gustavo Wambier, Flávio Adsuara Cadegiani
medRxiv 2021.06.28.21259661; doi: https://doi.org/10.1101/2021.06.28.21259661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)